Total Payments
$4,697
2024 Payments
$938.85
Companies
33
Transactions
95
Medicare Patients
2,242
Medicare Billing
$396,010
Payment Breakdown by Category
Food & Beverage$4,172 (88.8%)
Education$525.02 (11.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,172 | 88 | 88.8% |
| Education | $525.02 | 7 | 11.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $567.08 | 17 | $0 (2024) |
| Lilly USA, LLC | $535.13 | 9 | $0 (2023) |
| Merck Sharp & Dohme LLC | $359.15 | 9 | $0 (2024) |
| Seagen Inc. | $349.99 | 3 | $0 (2023) |
| Astellas Pharma US Inc | $345.01 | 3 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $263.98 | 2 | $0 (2024) |
| GENZYME CORPORATION | $252.62 | 2 | $0 (2024) |
| Genentech USA, Inc. | $231.48 | 7 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $181.08 | 5 | $0 (2023) |
| EMD Serono, Inc. | $158.11 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $938.85 | 9 | Merck Sharp & Dohme LLC ($202.81) |
| 2023 | $2,147 | 22 | Lilly USA, LLC ($477.49) |
| 2022 | $298.00 | 3 | E.R. Squibb & Sons, L.L.C. ($125.29) |
| 2020 | $125.31 | 1 | Genentech USA, Inc. ($125.31) |
| 2018 | $193.87 | 3 | Astellas Pharma US Inc ($125.00) |
| 2017 | $994.42 | 57 | Janssen Biotech, Inc. ($156.40) |
All Payment Transactions
95 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Food and Beverage | In-kind items and services | $82.81 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONC | ||||||
| 10/23/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $132.40 | General |
| Category: Oncology | ||||||
| 10/22/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA, OJJAARA | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $75.78 | General |
| Category: Oncology | ||||||
| 10/10/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $138.99 | General |
| Category: Oncology | ||||||
| 06/27/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $120.00 | General |
| Category: Oncology | ||||||
| 06/19/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $120.00 | General |
| Category: Oncology | ||||||
| 06/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $120.00 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2023 | EMD Serono, Inc. | BAVENCIO (Drug) | Food and Beverage | Cash or cash equivalent | $99.99 | General |
| Category: Oncology | ||||||
| 11/09/2023 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $125.71 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/12/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 09/13/2023 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Oncology | ||||||
| 08/30/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $109.91 | General |
| Category: Oncology | ||||||
| 08/09/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $120.22 | General |
| Category: Oncology | ||||||
| 08/07/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Oncology | ||||||
| 07/12/2023 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 05/30/2023 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: HEMATOLOGY | ||||||
| 05/18/2023 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $80.00 | General |
| Category: HORMONE THERAPY | ||||||
| 05/03/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $100.01 | General |
| Category: Oncology | ||||||
| 04/27/2023 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 04/20/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $74.93 | General |
| Category: ONCOLOGY | ||||||
| 03/30/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: Oncology | ||||||
| 03/22/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: Oncology | ||||||
| 03/15/2023 | Lilly USA, LLC | — | Food and Beverage | Cash or cash equivalent | $75.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 505 | 21,203 | $188,520 | $82,011 |
| 2022 | 12 | 588 | 28,213 | $228,813 | $103,263 |
| 2021 | 11 | 513 | 27,225 | $205,000 | $100,287 |
| 2020 | 13 | 636 | 29,689 | $262,789 | $110,449 |
Total Patients
2,242
Total Services
106,330
Medicare Billing
$396,010
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 196 | 393 | $68,046 | $34,098 | 50.1% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 14 | 20,250 | $42,120 | $17,777 | 42.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 62 | 83 | $20,382 | $9,947 | 48.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 44 | 44 | $12,183 | $4,873 | 40.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 21 | 21 | $7,722 | $3,260 | 42.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 34 | 39 | $4,629 | $2,444 | 52.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 20 | 22 | $5,995 | $2,390 | 39.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 22 | 25 | $4,836 | $1,849 | 38.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 22 | 164 | $10,168 | $1,803 | 17.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 16 | 34 | $9,027 | $1,560 | 17.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 15 | 30 | $2,123 | $1,273 | 60.0% |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | Office | 2023 | 20 | 50 | $1,092 | $696.57 | 63.8% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 19 | 48 | $197.28 | $40.40 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 189 | 415 | $68,834 | $38,847 | 56.4% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2022 | 21 | 27,000 | $56,160 | $24,075 | 42.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 78 | 111 | $26,113 | $14,083 | 53.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 64 | 64 | $23,232 | $9,879 | 42.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 35 | 72 | $5,096 | $2,936 | 57.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 26 | 52 | $13,806 | $2,559 | 18.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $5,364 | $2,345 | 43.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 31 | 38 | $4,293 | $2,334 | 54.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 30 | 31 | $7,927 | $2,331 | 29.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 29 | 179 | $11,098 | $1,855 | 16.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 11 | 104 | $5,460 | $1,141 | 20.9% |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | Office | 2022 | 27 | 64 | $1,172 | $823.34 | 70.2% |
About Dr. Markandu Ketheeswaran, MD
Dr. Markandu Ketheeswaran, MD is a Hematology & Oncology healthcare provider based in Fayetteville, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487608725.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Markandu Ketheeswaran, MD has received a total of $4,697 in payments from pharmaceutical and medical device companies, with $938.85 received in 2024. These payments were reported across 95 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($4,172).
As a Medicare-enrolled provider, Ketheeswaran has provided services to 2,242 Medicare beneficiaries, totaling 106,330 services with total Medicare billing of $396,010. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Fayetteville, NC
- Active Since 05/20/2006
- Last Updated 05/25/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1487608725
Products in Payments
- Tibsovo (Drug) $263.98
- SARCLISA (Biological) $252.62
- ZYTIGA (Drug) $246.99
- KEYTRUDA (Biological) $245.30
- TUKYSA (Drug) $225.00
- Xtandi (Drug) $220.01
- OPDIVO (Biological) $168.03
- Lenvima (Drug) $132.25
- ZEPZELCA (Drug) $125.71
- Alecensa (Biological) $125.31
- Trodelvy (Drug) $125.00
- XTANDI (Drug) $125.00
- BESREMI (Drug) $124.99
- MONJUVI (Drug) $124.99
- PADCEV (Biological) $124.99
- TECVAYLI (Biological) $124.99
- ERLEADA (Drug) $109.91
- IMBRUVICA (Drug) $109.36
- BRUKINSA (Drug) $100.00
- MONOFERRIC (Drug) $100.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fayetteville
Dr. Eric Schaefer, M.d, M.D
Hematology & Oncology — Payments: $343,754
Hematology & Oncology $343,754
Trevor Feinstein, M.d, M.D
Hematology & Oncology — Payments: $293,737
Hematology & Oncology $293,737
Dr. J Beck, M.d., F.a.c.p, M.D., F.A.C.P
Hematology & Oncology — Payments: $181,928
Hematology & Oncology $181,928
Dr. Patrick Travis, M.d, M.D
Hematology & Oncology — Payments: $69,474
Hematology & Oncology $69,474
Dr. Stephan Rosenfeld, M.d, M.D
Hematology & Oncology — Payments: $63,644
Hematology & Oncology $63,644
Dr. Tariq Nazir, M.d, M.D
Hematology & Oncology — Payments: $60,775
Hematology & Oncology $60,775